{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,19]],"date-time":"2026-02-19T03:39:33Z","timestamp":1771472373750,"version":"3.50.1"},"reference-count":101,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2023,11,24]],"date-time":"2023-11-24T00:00:00Z","timestamp":1700784000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,11,24]],"date-time":"2023-11-24T00:00:00Z","timestamp":1700784000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Heart Fail Rep"],"published-print":{"date-parts":[[2023,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Purpose of Review<\/jats:title>\n                <jats:p>With the widespread implementation of contemporary disease-modifying heart failure therapy, the rates of normalization of ejection fraction are continuously increasing. The TRED-HF trial confirmed that heart failure remission rather than complete recovery is typical in patients with dilated cardiomyopathy who respond to therapy. The present review outlines key points related to the management and knowledge gaps of this growing patient group, focusing on patients with non-ischaemic dilated cardiomyopathy.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Recent Findings<\/jats:title>\n                <jats:p>There is substantial heterogeneity among patients with normalized ejection fraction. The specific etiology is likely to affect the outcome, although a multiple-hit phenotype is frequent and may not be identified without comprehensive characterization. A monogenic or polygenic genetic susceptibility is common. Ongoing pathophysiological processes may be unraveled with advanced cardiac imaging, biomarkers, multi-omics, and machine learning technologies. There are limited studies that have investigated the withdrawal of specific heart failure therapies in these patients. Diuretics may be safely withdrawn if there is no evidence of congestion, while continued therapy with at least some disease-modifying therapy is likely to be required to reduce myocardial workload and sustain remission for the vast majority.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Summary<\/jats:title>\n                <jats:p>Understanding the underlying disease mechanisms of patients with normalized ejection fraction is crucial in identifying markers of myocardial relapse and guiding individualized therapy in the future. Ongoing clinical trials should inform personalized approaches to therapy.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1007\/s11897-023-00636-8","type":"journal-article","created":{"date-parts":[[2023,11,24]],"date-time":"2023-11-24T08:02:55Z","timestamp":1700812975000},"page":"542-554","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Your Heart Function Has Normalized\u2014What Next After TRED-HF?"],"prefix":"10.1007","volume":"20","author":[{"given":"Alexandros","family":"Kasiakogias","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aaraby","family":"Ragavan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Brian P.","family":"Halliday","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2023,11,24]]},"reference":[{"key":"636_CR1","doi-asserted-by":"publisher","first-page":"3599","DOI":"10.1093\/eurheartj\/ehab368","volume":"42","author":"TA McDonagh","year":"2021","unstructured":"McDonagh TA, Metra M, Adamo M, Gardner RS, Baumbach A, B\u00f6hm M, et al. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J. 2021;42:3599\u2013726. https:\/\/doi.org\/10.1093\/eurheartj\/ehab368.","journal-title":"Eur Heart J"},{"key":"636_CR2","doi-asserted-by":"publisher","first-page":"e895","DOI":"10.1161\/CIR.0000000000001063","volume":"145","author":"PA Heidenreich","year":"2022","unstructured":"Heidenreich PA, Bozkurt B, Aguilar D, Allen LA, Byun JJ, Colvin MM, et al. 2022 AHA\/ACC\/HFSA guideline for the management of heart failure: a report of the American College of Cardiology\/American Heart Association Joint Committee on clinical practice guidelines. Circulation. 2022;145:e895-1032. https:\/\/doi.org\/10.1161\/CIR.0000000000001063.","journal-title":"Circulation"},{"key":"636_CR3","doi-asserted-by":"publisher","first-page":"719","DOI":"10.1016\/j.jacc.2020.05.075","volume":"76","author":"JE Wilcox","year":"2020","unstructured":"Wilcox JE, Fang JC, Margulies KB, Mann DL. Heart failure with recovered left ventricular ejection fraction. J Am Coll Cardiol. 2020;76:719\u201334. https:\/\/doi.org\/10.1016\/j.jacc.2020.05.075.","journal-title":"J Am Coll Cardiol"},{"key":"636_CR4","doi-asserted-by":"publisher","first-page":"1180","DOI":"10.1002\/ejhf.2571","volume":"24","author":"A Ragavan","year":"2022","unstructured":"Ragavan A, Hogan J, Halliday BP. The spectrum of heart failure with improved ejection fraction: persistent congestion, to heart failure remission and perhaps recovery? Eur J Heart Fail. 2022;24:1180\u20132. https:\/\/doi.org\/10.1002\/ejhf.2571.","journal-title":"Eur J Heart Fail"},{"key":"636_CR5","doi-asserted-by":"publisher","first-page":"500","DOI":"10.1016\/j.jacbts.2022.03.008","volume":"7","author":"BP Halliday","year":"2022","unstructured":"Halliday BP, Cleland JGF. Maintaining success for patients with dilated cardiomyopathy and remission of heart failure. JACC Basic Transl Sci. 2022;7:500\u20133. https:\/\/doi.org\/10.1016\/j.jacbts.2022.03.008.","journal-title":"JACC Basic Transl Sci"},{"key":"636_CR6","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1016\/S0140-6736(18)32484-X","volume":"393","author":"BP Halliday","year":"2019","unstructured":"Halliday BP, Wassall R, Lota AS, Khalique Z, Gregson J, Newsome S, et al. Withdrawal of pharmacological treatment for heart failure in patients with recovered dilated cardiomyopathy (TRED-HF): an open-label, pilot, randomised trial. Lancet Lond Engl. 2019;393:61\u201373. https:\/\/doi.org\/10.1016\/S0140-6736(18)32484-X.","journal-title":"Lancet Lond Engl"},{"key":"636_CR7","doi-asserted-by":"publisher","unstructured":"Arbelo E, Protonotarios A, Gimeno JR, Arbustini E, Barriales-Villa R, Basso C, et al. 2023 ESC Guidelines for the management of cardiomyopathies: developed by the task force on the management of cardiomyopathies of the European Society of Cardiology (ESC). Eur Heart J. 2023;ehad194. https:\/\/doi.org\/10.1093\/eurheartj\/ehad194.","DOI":"10.1093\/eurheartj\/ehad194"},{"key":"636_CR8","doi-asserted-by":"publisher","first-page":"466","DOI":"10.1080\/24748706.2021.1954275","volume":"5","author":"J Boulet","year":"2021","unstructured":"Boulet J, Mehra MR. Left ventricular reverse remodeling in heart failure: remission to recovery. Struct Heart. 2021;5:466\u201381. https:\/\/doi.org\/10.1080\/24748706.2021.1954275.","journal-title":"Struct Heart"},{"key":"636_CR9","doi-asserted-by":"publisher","first-page":"e006833","DOI":"10.1161\/CIRCHEARTFAILURE.119.006833","volume":"13","author":"AD DeVore","year":"2020","unstructured":"DeVore AD, Hellkamp AS, Thomas L, Albert NM, Butler J, Patterson JH, et al. Improvement in left ventricular ejection fraction in outpatients with heart failure with reduced ejection fraction. Circ Heart Fail. 2020;13:e006833. https:\/\/doi.org\/10.1161\/CIRCHEARTFAILURE.119.006833.","journal-title":"Circ Heart Fail"},{"key":"636_CR10","doi-asserted-by":"publisher","first-page":"2110","DOI":"10.1093\/eurheartj\/ehz233","volume":"40","author":"A Ghimire","year":"2019","unstructured":"Ghimire A, Fine N, Ezekowitz JA, Howlett J, Youngson E, McAlister FA. Frequency, predictors, and prognosis of ejection fraction improvement in heart failure: an echocardiogram-based registry study. Eur Heart J. 2019;40:2110\u20137. https:\/\/doi.org\/10.1093\/eurheartj\/ehz233.","journal-title":"Eur Heart J"},{"key":"636_CR11","doi-asserted-by":"publisher","first-page":"1160","DOI":"10.1002\/ejhf.1734","volume":"22","author":"U Tayal","year":"2020","unstructured":"Tayal U, Wage R, Newsome S, Manivarmane R, Izgi C, Muthumala A, et al. Predictors of left ventricular remodelling in patients with dilated cardiomyopathy - a cardiovascular magnetic resonance study. Eur J Heart Fail. 2020;22:1160\u201370. https:\/\/doi.org\/10.1002\/ejhf.1734.","journal-title":"Eur J Heart Fail"},{"key":"636_CR12","doi-asserted-by":"publisher","first-page":"2380","DOI":"10.1161\/CIRCULATIONAHA.113.006855","volume":"129","author":"A Basuray","year":"2014","unstructured":"Basuray A, French B, Ky B, Vorovich E, Olt C, Sweitzer NK, et al. Heart failure with recovered ejection fraction: clinical description, biomarkers, and outcomes. Circulation. 2014;129:2380\u20137. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.113.006855.","journal-title":"Circulation"},{"key":"636_CR13","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1016\/j.jchf.2018.11.019","volume":"7","author":"G Savarese","year":"2019","unstructured":"Savarese G, Vedin O, D\u2019Amario D, Uijl A, Dahlstr\u00f6m U, Rosano G, et al. Prevalence and prognostic implications of longitudinal ejection fraction change in heart failure. JACC Heart Fail. 2019;7:306\u201317. https:\/\/doi.org\/10.1016\/j.jchf.2018.11.019. This study investigated LVEF trajectories in a large registry and reported on associated variables.","journal-title":"JACC Heart Fail"},{"key":"636_CR14","doi-asserted-by":"publisher","first-page":"1615","DOI":"10.1002\/ejhf.824","volume":"19","author":"J Lup\u00f3n","year":"2017","unstructured":"Lup\u00f3n J, D\u00edez-L\u00f3pez C, de Antonio M, Domingo M, Zamora E, Moliner P, et al. Recovered heart failure with reduced ejection fraction and outcomes: a prospective study. Eur J Heart Fail. 2017;19:1615\u201323. https:\/\/doi.org\/10.1002\/ejhf.824.","journal-title":"Eur J Heart Fail"},{"key":"636_CR15","doi-asserted-by":"publisher","first-page":"1171","DOI":"10.1002\/ejhf.2512","volume":"24","author":"P Manca","year":"2022","unstructured":"Manca P, Stolfo D, Merlo M, Gregorio C, Cannat\u00e0 A, Ramani F, et al. Transient versus persistent improved ejection fraction in non-ischaemic dilated cardiomyopathy. Eur J Heart Fail. 2022;24:1171\u20139. https:\/\/doi.org\/10.1002\/ejhf.2512. This study examined the clinical course of transient versus persistent improvement in LVEF in patients with non-ischemic cardiomyopathy.","journal-title":"Eur J Heart Fail"},{"key":"636_CR16","doi-asserted-by":"publisher","first-page":"e147","DOI":"10.1016\/S0828-282X(09)70497-0","volume":"25","author":"J Moon","year":"2009","unstructured":"Moon J, Ko Y-G, Chung N, Ha J-W, Kang S-M, Choi E-Y, et al. Recovery and recurrence of left ventricular systolic dysfunction in patients with idiopathic dilated cardiomyopathy. Can J Cardiol. 2009;25:e147\u201350. https:\/\/doi.org\/10.1016\/S0828-282X(09)70497-0.","journal-title":"Can J Cardiol"},{"key":"636_CR17","doi-asserted-by":"publisher","first-page":"e001504","DOI":"10.1161\/JAHA.114.000570","volume":"4","author":"M Merlo","year":"2015","unstructured":"Merlo M, Stolfo D, Anzini M, Negri F, Pinamonti B, Barbati G, et al. Persistent recovery of normal left ventricular function and dimension in idiopathic dilated cardiomyopathy during long-term follow-up: does real healing exist? J Am Heart Assoc. 2015;4:e001504. https:\/\/doi.org\/10.1161\/JAHA.114.000570.","journal-title":"J Am Heart Assoc"},{"key":"636_CR18","doi-asserted-by":"publisher","first-page":"510","DOI":"10.1001\/jamacardio.2016.1325","volume":"1","author":"AP Kalogeropoulos","year":"2016","unstructured":"Kalogeropoulos AP, Fonarow GC, Georgiopoulou V, Burkman G, Siwamogsatham S, Patel A, et al. Characteristics and outcomes of adult outpatients with heart failure and improved or recovered ejection fraction. JAMA Cardiol. 2016;1:510\u20138. https:\/\/doi.org\/10.1001\/jamacardio.2016.1325.","journal-title":"JAMA Cardiol"},{"key":"636_CR19","doi-asserted-by":"publisher","first-page":"e002826","DOI":"10.1161\/CIRCHEARTFAILURE.115.002826","volume":"9","author":"W Nadruz","year":"2016","unstructured":"Nadruz W, West E, Santos M, Skali H, Groarke JD, Forman DE, et al. Heart failure and midrange ejection fraction. Circ Heart Fail. 2016;9:e002826. https:\/\/doi.org\/10.1161\/CIRCHEARTFAILURE.115.002826.","journal-title":"Circ Heart Fail"},{"key":"636_CR20","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1016\/j.jchf.2021.03.010","volume":"9","author":"BP Halliday","year":"2021","unstructured":"Halliday BP, Vazir A, Owen R, Gregson J, Wassall R, Lota AS, et al. Heart rate as a marker of relapse during withdrawal of therapy in recovered dilated cardiomyopathy. JACC Heart Fail. 2021;9:509\u201317. https:\/\/doi.org\/10.1016\/j.jchf.2021.03.010. An analysis of the TRED-HF trial identified the association of heart rate following withdrawal of therapy with myocardial relapse.","journal-title":"JACC Heart Fail"},{"key":"636_CR21","doi-asserted-by":"publisher","first-page":"1616","DOI":"10.1002\/ehf2.13872","volume":"9","author":"BP Halliday","year":"2022","unstructured":"Halliday BP, Owen R, Gregson J, Vazir A, Wassall R, Khalique Z, et al. Changes in clinical and imaging variables during withdrawal of heart failure therapy in recovered dilated cardiomyopathy. ESC Heart Fail. 2022;9:1616\u201324. https:\/\/doi.org\/10.1002\/ehf2.13872.","journal-title":"ESC Heart Fail"},{"key":"636_CR22","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1002\/ejhf.2063","volume":"23","author":"BP Halliday","year":"2021","unstructured":"Halliday BP, Owen R, Gregson J, S Vassiliou V, Chen X, Wage R, et al. Myocardial remodelling after withdrawing therapy for heart failure in patients with recovered dilated cardiomyopathy: insights from TRED-HF. Eur J Heart Fail. 2021;23:293\u2013301. https:\/\/doi.org\/10.1002\/ejhf.2063.","journal-title":"Eur J Heart Fail"},{"key":"636_CR23","doi-asserted-by":"publisher","first-page":"1123","DOI":"10.1161\/CIRCULATIONAHA.121.058457","volume":"146","author":"AS Lota","year":"2022","unstructured":"Lota AS, Hazebroek MR, Theotokis P, Wassall R, Salmi S, Halliday BP, et al. Genetic architecture of acute myocarditis and the overlap with inherited cardiomyopathy. Circulation. 2022;146:1123\u201334. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.121.058457. An analysis of patients with acute myocarditis showed a high prevalence of dilated and arrhythmogenic cardiomyopathy-associated genes.","journal-title":"Circulation"},{"key":"636_CR24","doi-asserted-by":"publisher","first-page":"2293","DOI":"10.1016\/j.jacc.2018.03.462","volume":"71","author":"JS Ware","year":"2018","unstructured":"Ware JS, Amor-Salamanca A, Tayal U, Govind R, Serrano I, Salazar-Mendiguch\u00eda J, et al. Genetic etiology for alcohol-induced cardiac toxicity. J Am Coll Cardiol. 2018;71:2293\u2013302. https:\/\/doi.org\/10.1016\/j.jacc.2018.03.462.","journal-title":"J Am Coll Cardiol"},{"key":"636_CR25","doi-asserted-by":"publisher","first-page":"2254","DOI":"10.1038\/s41467-020-15823-7","volume":"11","author":"JP Pirruccello","year":"2020","unstructured":"Pirruccello JP, Bick A, Wang M, Chaffin M, Friedman S, Yao J, et al. Analysis of cardiac magnetic resonance imaging in 36,000 individuals yields genetic insights into dilated cardiomyopathy. Nat Commun. 2020;11:2254. https:\/\/doi.org\/10.1038\/s41467-020-15823-7.","journal-title":"Nat Commun"},{"key":"636_CR26","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1016\/j.jaccao.2020.09.006","volume":"2","author":"S Bhatia","year":"2020","unstructured":"Bhatia S. Genetics of anthracycline cardiomyopathy in cancer survivors. JACC CardioOncology. 2020;2:539\u201352. https:\/\/doi.org\/10.1016\/j.jaccao.2020.09.006.","journal-title":"JACC CardioOncology"},{"key":"636_CR27","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1161\/CIRCULATIONAHA.118.037934","volume":"140","author":"P Garcia-Pavia","year":"2019","unstructured":"Garcia-Pavia P, Kim Y, Restrepo-Cordoba MA, Lunde IG, Wakimoto H, Smith AM, et al. Genetic variants associated with cancer therapy\u2013induced cardiomyopathy. Circulation. 2019;140:31\u201341. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.118.037934.","journal-title":"Circulation"},{"key":"636_CR28","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1016\/j.jacc.2019.11.014","volume":"75","author":"MB Davis","year":"2020","unstructured":"Davis MB, Arany Z, McNamara DM, Goland S, Elkayam U. Peripartum cardiomyopathy: JACC state-of-the-art review. J Am Coll Cardiol. 2020;75:207\u201321. https:\/\/doi.org\/10.1016\/j.jacc.2019.11.014.","journal-title":"J Am Coll Cardiol"},{"key":"636_CR29","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1016\/j.amjcard.2023.01.043","volume":"194","author":"D Koerber","year":"2023","unstructured":"Koerber D, Khan S, Kirubarajan A, Spivak A, Wine R, Matelski J, et al. Meta-analysis of long-term (> 1 year) cardiac outcomes of peripartum cardiomyopathy. Am J Cardiol. 2023;194:71\u20137. https:\/\/doi.org\/10.1016\/j.amjcard.2023.01.043.","journal-title":"Am J Cardiol"},{"key":"636_CR30","doi-asserted-by":"publisher","unstructured":"Davis MB, Sliwa K. To infinity and beyond. JACC Heart Fail. 2023;S2213177923004079. https:\/\/doi.org\/10.1016\/j.jchf.2023.06.035.","DOI":"10.1016\/j.jchf.2023.06.035"},{"key":"636_CR31","doi-asserted-by":"publisher","DOI":"10.1016\/j.jchf.2023.05.031","author":"JP Lovell","year":"2023","unstructured":"Lovell JP, Bermea K, Yu J, Rousseau S, Cohen CD, Bhalodia A, et al. Serum proteomic analysis of peripartum cardiomyopathy reveals distinctive dysregulation of inflammatory and cholesterol metabolism pathways. JACC Heart Fail. 2023. https:\/\/doi.org\/10.1016\/j.jchf.2023.05.031.","journal-title":"JACC Heart Fail"},{"key":"636_CR32","doi-asserted-by":"publisher","first-page":"624216","DOI":"10.3389\/fcell.2020.624216","volume":"8","author":"D Ramaccini","year":"2021","unstructured":"Ramaccini D, Montoya-Uribe V, Aan FJ, Modesti L, Potes Y, Wieckowski MR, et al. Mitochondrial function and dysfunction in dilated cardiomyopathy. Front Cell Dev Biol. 2021;8:624216. https:\/\/doi.org\/10.3389\/fcell.2020.624216.","journal-title":"Front Cell Dev Biol"},{"key":"636_CR33","doi-asserted-by":"publisher","first-page":"1852","DOI":"10.1161\/CIRCULATIONAHA.120.052395","volume":"143","author":"R Goli","year":"2021","unstructured":"Goli R, Li J, Brandimarto J, Levine LD, Riis V, McAfee Q, et al. Genetic and phenotypic landscape of peripartum cardiomyopathy. Circulation. 2021;143:1852\u201362. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.120.052395.","journal-title":"Circulation"},{"key":"636_CR34","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1056\/NEJMoa1505517","volume":"374","author":"JS Ware","year":"2016","unstructured":"Ware JS, Li J, Mazaika E, Yasso CM, DeSouza T, Cappola TP, et al. Shared genetic predisposition in peripartum and dilated cardiomyopathies. N Engl J Med. 2016;374:233\u201341. https:\/\/doi.org\/10.1056\/NEJMoa1505517.","journal-title":"N Engl J Med"},{"key":"636_CR35","doi-asserted-by":"publisher","first-page":"2745","DOI":"10.1002\/ehf2.14395","volume":"10","author":"E Bertero","year":"2023","unstructured":"Bertero E, Fracasso G, Eustachi V, Coviello D, Cecconi M, Giovinazzo S, et al. Diagnostic yield and predictive value on left ventricular remodelling of genetic testing in dilated cardiomyopathy. ESC Heart Fail. 2023;10:2745\u201350. https:\/\/doi.org\/10.1002\/ehf2.14395.","journal-title":"ESC Heart Fail"},{"key":"636_CR36","doi-asserted-by":"publisher","first-page":"1704","DOI":"10.1136\/heartjnl-2016-311017","volume":"103","author":"M Dal Ferro","year":"2017","unstructured":"Dal Ferro M, Stolfo D, Altinier A, Gigli M, Perrieri M, Ramani F, et al. Association between mutation status and left ventricular reverse remodelling in dilated cardiomyopathy. Heart Br Card Soc. 2017;103:1704\u201310. https:\/\/doi.org\/10.1136\/heartjnl-2016-311017.","journal-title":"Heart Br Card Soc"},{"key":"636_CR37","doi-asserted-by":"publisher","first-page":"1682","DOI":"10.1016\/j.jacc.2021.08.039","volume":"78","author":"L Escobar-Lopez","year":"2021","unstructured":"Escobar-Lopez L, Ochoa JP, Mirelis JG, Espinosa M\u00c1, Navarro M, Gallego-Delgado M, et al. Association of genetic variants with outcomes in patients with nonischemic dilated cardiomyopathy. J Am Coll Cardiol. 2021;78:1682\u201399. https:\/\/doi.org\/10.1016\/j.jacc.2021.08.039. A retrospective study of genotyped patients with DCM that provided information on prognosis by genetic profile.","journal-title":"J Am Coll Cardiol"},{"key":"636_CR38","doi-asserted-by":"publisher","first-page":"2384","DOI":"10.1093\/eurheartj\/ehab286","volume":"42","author":"U Tayal","year":"2021","unstructured":"Tayal U, Ware JS, Lakdawala NK, Heymans S, Prasad SK. Understanding the genetics of adult-onset dilated cardiomyopathy: what a clinician needs to know. Eur Heart J. 2021;42:2384\u201396. https:\/\/doi.org\/10.1093\/eurheartj\/ehab286.","journal-title":"Eur Heart J"},{"key":"636_CR39","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1002\/ejhf.673","volume":"19","author":"JA Jansweijer","year":"2017","unstructured":"Jansweijer JA, Nieuwhof K, Russo F, Hoorntje ET, Jongbloed JDH, Lekanne Deprez RH, et al. Truncating titin mutations are associated with a mild and treatable form of dilated cardiomyopathy. Eur J Heart Fail. 2017;19:512\u201321. https:\/\/doi.org\/10.1002\/ejhf.673.","journal-title":"Eur J Heart Fail"},{"key":"636_CR40","doi-asserted-by":"publisher","first-page":"e005220","DOI":"10.1161\/CIRCHEARTFAILURE.118.005220","volume":"11","author":"JAJ Verdonschot","year":"2018","unstructured":"Verdonschot JAJ, Hazebroek MR, Wang P, Sanders-van Wijk S, Merken JJ, Adriaansen YA, et al. Clinical phenotype and genotype associations with improvement in left ventricular function in dilated cardiomyopathy. Circ Heart Fail. 2018;11:e005220. https:\/\/doi.org\/10.1161\/CIRCHEARTFAILURE.118.005220.","journal-title":"Circ Heart Fail"},{"key":"636_CR41","doi-asserted-by":"publisher","first-page":"700","DOI":"10.1001\/jamacardio.2017.0763","volume":"2","author":"K Luk","year":"2017","unstructured":"Luk K, Bakhsh A, Giannetti N, Elstein E, Lathrop M, Thanassoulis G, et al. Recovery in patients with dilated cardiomyopathy with loss-of-function mutations in the titin gene. JAMA Cardiol. 2017;2:700\u20132. https:\/\/doi.org\/10.1001\/jamacardio.2017.0763.","journal-title":"JAMA Cardiol"},{"key":"636_CR42","doi-asserted-by":"publisher","first-page":"e009352","DOI":"10.1161\/CIRCHEARTFAILURE.121.009352","volume":"15","author":"MTHM Henkens","year":"2022","unstructured":"Henkens MTHM, Stroeks SLVM, Raafs AG, Sikking MA, Tromp J, Ouwerkerk W, et al. Dynamic ejection fraction trajectory in patients with dilated cardiomyopathy with a truncating titin variant. Circ Heart Fail. 2022;15:e009352. https:\/\/doi.org\/10.1161\/CIRCHEARTFAILURE.121.009352.","journal-title":"Circ Heart Fail"},{"key":"636_CR43","doi-asserted-by":"publisher","first-page":"e006832","DOI":"10.1161\/CIRCHEARTFAILURE.119.006832","volume":"13","author":"MM Akhtar","year":"2020","unstructured":"Akhtar MM, Lorenzini M, Cicerchia M, Ochoa JP, Hey TM, Sabater Molina M, et al. Clinical phenotypes and prognosis of dilated cardiomyopathy caused by truncating variants in the TTN gene. Circ Heart Fail. 2020;13:e006832. https:\/\/doi.org\/10.1161\/CIRCHEARTFAILURE.119.006832.","journal-title":"Circ Heart Fail"},{"key":"636_CR44","doi-asserted-by":"publisher","first-page":"864","DOI":"10.1093\/eurheartj\/ehx808","volume":"39","author":"JAJ Verdonschot","year":"2018","unstructured":"Verdonschot JAJ, Hazebroek MR, Derks KWJ, Barandiar\u00e1n Aizpurua A, Merken JJ, Wang P, et al. Titin cardiomyopathy leads to altered mitochondrial energetics, increased fibrosis and long-term life-threatening arrhythmias. Eur Heart J. 2018;39:864\u201373. https:\/\/doi.org\/10.1093\/eurheartj\/ehx808.","journal-title":"Eur Heart J"},{"key":"636_CR45","doi-asserted-by":"publisher","first-page":"2921","DOI":"10.1016\/j.jacc.2019.10.011","volume":"74","author":"D Fatkin","year":"2019","unstructured":"Fatkin D, Huttner IG, Kovacic JC, Seidman JG, Seidman CE. Precision medicine in the management of dilated cardiomyopathy: JACC state-of-the-art review. J Am Coll Cardiol. 2019;74:2921\u201338. https:\/\/doi.org\/10.1016\/j.jacc.2019.10.011.","journal-title":"J Am Coll Cardiol"},{"key":"636_CR46","doi-asserted-by":"publisher","first-page":"e003788","DOI":"10.1161\/CIRCHEARTFAILURE.116.003788","volume":"10","author":"L Adamo","year":"2017","unstructured":"Adamo L, Perry A, Novak E, Makan M, Lindman BR, Mann DL. Abnormal global longitudinal strain predicts future deterioration of left ventricular function in heart failure patients with a recovered left ventricular ejection fraction. Circ Heart Fail. 2017;10:e003788. https:\/\/doi.org\/10.1161\/CIRCHEARTFAILURE.116.003788.","journal-title":"Circ Heart Fail"},{"key":"636_CR47","doi-asserted-by":"publisher","first-page":"710","DOI":"10.1136\/heartjnl-2021-319504","volume":"108","author":"M Merlo","year":"2022","unstructured":"Merlo M, Mas\u00e8 M, Perry A, Franca EL, Deych E, Ajello L, et al. Prognostic significance of longitudinal strain in dilated cardiomyopathy with recovered ejection fraction. Heart. 2022;108:710\u20136. https:\/\/doi.org\/10.1136\/heartjnl-2021-319504. This study examined the association of global longitudinal strain with outcomes in patients with normalized LVEF.","journal-title":"Heart"},{"key":"636_CR48","doi-asserted-by":"publisher","first-page":"e024505","DOI":"10.1161\/JAHA.121.024505","volume":"11","author":"AG Raafs","year":"2022","unstructured":"Raafs AG, Boscutti A, Henkens MTHM, van den Broek WWA, Verdonschot JAJ, Weerts J, et al. Global longitudinal strain is incremental to left ventricular ejection fraction for the prediction of outcome in optimally treated dilated cardiomyopathy patients. J Am Heart Assoc. 2022;11:e024505. https:\/\/doi.org\/10.1161\/JAHA.121.024505.","journal-title":"J Am Heart Assoc"},{"key":"636_CR49","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/j.jchf.2021.08.007","volume":"10","author":"S Janwanishstaporn","year":"2022","unstructured":"Janwanishstaporn S, Cho JY, Feng S, Brann A, Seo J-S, Narezkina A, et al. Prognostic value of global longitudinal strain in patients with heart failure with improved ejection fraction. JACC Heart Fail. 2022;10:27\u201337. https:\/\/doi.org\/10.1016\/j.jchf.2021.08.007.","journal-title":"JACC Heart Fail"},{"key":"636_CR50","doi-asserted-by":"publisher","first-page":"1557","DOI":"10.1016\/j.jacc.2018.06.070","volume":"72","author":"J Merken","year":"2018","unstructured":"Merken J, Brunner-La Rocca H-P, Weerts J, Verdonschot J, Hazebroek M, Schummers G, et al. Heart failure with recovered ejection fraction. J Am Coll Cardiol. 2018;72:1557\u20138. https:\/\/doi.org\/10.1016\/j.jacc.2018.06.070.","journal-title":"J Am Coll Cardiol"},{"key":"636_CR51","doi-asserted-by":"publisher","first-page":"e026891","DOI":"10.1161\/JAHA.122.026891","volume":"12","author":"Y Sun","year":"2023","unstructured":"Sun Y, Chen X, Zhang Y, Yu Y, Zhang X, Si J, et al. Reverse atrial remodeling in heart failure with recovered ejection fraction. J Am Heart Assoc. 2023;12:e026891. https:\/\/doi.org\/10.1161\/JAHA.122.026891.","journal-title":"J Am Heart Assoc"},{"key":"636_CR52","doi-asserted-by":"publisher","first-page":"8768","DOI":"10.1038\/s41598-022-12823-z","volume":"12","author":"T Takada","year":"2022","unstructured":"Takada T, Matsuura K, Minami Y, Abe T, Yoshida A, Kishihara M, et al. Prognosis and diastolic dysfunction predictors in patients with heart failure and recovered ejection fraction. Sci Rep. 2022;12:8768. https:\/\/doi.org\/10.1038\/s41598-022-12823-z.","journal-title":"Sci Rep"},{"key":"636_CR53","doi-asserted-by":"publisher","first-page":"1645","DOI":"10.1016\/j.jcmg.2018.07.015","volume":"12","author":"BP Halliday","year":"2019","unstructured":"Halliday BP, Baksi AJ, Gulati A, Ali A, Newsome S, Izgi C, et al. Outcome in dilated cardiomyopathy related to the extent, location, and pattern of late gadolinium enhancement. JACC Cardiovasc Imaging. 2019;12:1645\u201355. https:\/\/doi.org\/10.1016\/j.jcmg.2018.07.015.","journal-title":"JACC Cardiovasc Imaging"},{"key":"636_CR54","doi-asserted-by":"publisher","first-page":"1351","DOI":"10.1016\/j.jcmg.2021.03.015","volume":"14","author":"SK Prasad","year":"2021","unstructured":"Prasad SK, Halliday BP. Myocardial fibrosis in dilated cardiomyopathy: moving from stratifying risk to improving outcomes\u2217. JACC Cardiovasc Imaging. 2021;14:1351\u20133. https:\/\/doi.org\/10.1016\/j.jcmg.2021.03.015.","journal-title":"JACC Cardiovasc Imaging"},{"key":"636_CR55","doi-asserted-by":"publisher","first-page":"1274","DOI":"10.1016\/j.jcmg.2018.03.006","volume":"11","author":"MAJ Becker","year":"2018","unstructured":"Becker MAJ, Cornel JH, van de Ven PM, van Rossum AC, Allaart CP, Germans T. The prognostic value of late gadolinium-enhanced cardiac magnetic resonance imaging in nonischemic dilated cardiomyopathy: a review and meta-analysis. JACC Cardiovasc Imaging. 2018;11:1274\u201384. https:\/\/doi.org\/10.1016\/j.jcmg.2018.03.006.","journal-title":"JACC Cardiovasc Imaging"},{"key":"636_CR56","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1002\/ehf2.13133","volume":"8","author":"T Nabeta","year":"2021","unstructured":"Nabeta T, Ishii S, Ikeda Y, Maemura K, Oki T, Yazaki M, et al. Late gadolinium enhancement for re-worsening left ventricular ejection fraction in patients with dilated cardiomyopathy. ESC Heart Fail. 2021;8:615\u201324. https:\/\/doi.org\/10.1002\/ehf2.13133.","journal-title":"ESC Heart Fail"},{"key":"636_CR57","doi-asserted-by":"publisher","unstructured":"Saraste A, Knuuti J, Bengel F. Phenotyping heart failure by nuclear imaging of myocardial perfusion, metabolism, and molecular targets. Eur Heart J - Cardiovasc Imaging. 2023;jead128. https:\/\/doi.org\/10.1093\/ehjci\/jead128.","DOI":"10.1093\/ehjci\/jead128"},{"key":"636_CR58","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1161\/ATVBAHA.122.318731","volume":"43","author":"R-S Wang","year":"2023","unstructured":"Wang R-S, Maron BA, Loscalzo J. Multiomics network medicine approaches to precision medicine and therapeutics in cardiovascular diseases. Arterioscler Thromb Vasc Biol. 2023;43:493\u2013503. https:\/\/doi.org\/10.1161\/ATVBAHA.122.318731.","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"636_CR59","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1038\/s41569-020-00477-1","volume":"18","author":"A Joshi","year":"2021","unstructured":"Joshi A, Rienks M, Theofilatos K, Mayr M. Systems biology in cardiovascular disease: a multiomics approach. Nat Rev Cardiol. 2021;18:313\u201330. https:\/\/doi.org\/10.1038\/s41569-020-00477-1. A state-of-the-art review that discusses the utility of different omics data for the study of cardiovascular disease.","journal-title":"Nat Rev Cardiol"},{"key":"636_CR60","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1093\/ehjci\/jeab227","volume":"23","author":"KB Hansen","year":"2022","unstructured":"Hansen KB, S\u00f6rensen J, Hansson NH, Nielsen R, Larsen AH, Fr\u00f8ki\u00e6r J, et al. Myocardial efficiency in patients with different aetiologies and stages of heart failure. Eur Heart J Cardiovasc Imaging. 2022;23:328\u201337. https:\/\/doi.org\/10.1093\/ehjci\/jeab227.","journal-title":"Eur Heart J Cardiovasc Imaging"},{"key":"636_CR61","doi-asserted-by":"publisher","first-page":"1810","DOI":"10.1161\/01.cir.86.6.1810","volume":"86","author":"S Neubauer","year":"1992","unstructured":"Neubauer S, Krahe T, Schindler R, Horn M, Hillenbrand H, Entzeroth C, et al. 31P magnetic resonance spectroscopy in dilated cardiomyopathy and coronary artery disease. Altered cardiac high-energy phosphate metabolism in heart failure. Circulation. 1992;86:1810\u20138. https:\/\/doi.org\/10.1161\/01.cir.86.6.1810.","journal-title":"Circulation"},{"key":"636_CR62","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1093\/ehjci\/jeac242","volume":"24","author":"AK Barton","year":"2022","unstructured":"Barton AK, Tzolos E, Bing R, Singh T, Weber W, Schwaiger M, et al. Emerging molecular imaging targets and tools for myocardial fibrosis detection. Eur Heart J Cardiovasc Imaging. 2022;24:261\u201375. https:\/\/doi.org\/10.1093\/ehjci\/jeac242.","journal-title":"Eur Heart J Cardiovasc Imaging"},{"key":"636_CR63","doi-asserted-by":"publisher","first-page":"e010628","DOI":"10.1161\/CIRCIMAGING.120.010628","volume":"13","author":"MB Heckmann","year":"2020","unstructured":"Heckmann MB, Reinhardt F, Finke D, Katus HA, Haberkorn U, Leuschner F, et al. Relationship between cardiac fibroblast activation protein activity by positron emission tomography and cardiovascular disease. Circ Cardiovasc Imaging. 2020;13:e010628. https:\/\/doi.org\/10.1161\/CIRCIMAGING.120.010628.","journal-title":"Circ Cardiovasc Imaging"},{"key":"636_CR64","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1126\/science.abm0594","volume":"375","author":"JG Rurik","year":"2022","unstructured":"Rurik JG, Tomb\u00e1cz I, Yadegari A, M\u00e9ndez Fern\u00e1ndez PO, Shewale SV, Li L, et al. CAR T cells produced in vivo to treat cardiac injury. Science. 2022;375:91\u20136. https:\/\/doi.org\/10.1126\/science.abm0594.","journal-title":"Science"},{"key":"636_CR65","doi-asserted-by":"publisher","first-page":"895836","DOI":"10.3389\/fcvm.2022.895836","volume":"9","author":"J Sun","year":"2022","unstructured":"Sun J, Guo H, Wang W, Wang X, Ding J, He K, et al. Identifying novel subgroups in heart failure patients with unsupervised machine learning: a scoping review. Front Cardiovasc Med. 2022;9:895836. https:\/\/doi.org\/10.3389\/fcvm.2022.895836.","journal-title":"Front Cardiovasc Med"},{"key":"636_CR66","doi-asserted-by":"publisher","first-page":"2219","DOI":"10.1016\/j.jacc.2022.03.375","volume":"79","author":"U Tayal","year":"2022","unstructured":"Tayal U, Verdonschot JAJ, Hazebroek MR, Howard J, Gregson J, Newsome S, et al. Precision phenotyping of dilated cardiomyopathy using multidimensional data. J Am Coll Cardiol. 2022;79:2219\u201332. https:\/\/doi.org\/10.1016\/j.jacc.2022.03.375. This trial utilized machine learning on multiparametric data to identify mechanistically distinct DCM subtypes.","journal-title":"J Am Coll Cardiol"},{"key":"636_CR67","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1093\/eurheartj\/ehaa841","volume":"42","author":"JAJ Verdonschot","year":"2021","unstructured":"Verdonschot JAJ, Merlo M, Dominguez F, Wang P, Henkens MTHM, Adriaens ME, et al. Phenotypic clustering of dilated cardiomyopathy patients highlights important pathophysiological differences. Eur Heart J. 2021;42:162\u201374. https:\/\/doi.org\/10.1093\/eurheartj\/ehaa841.","journal-title":"Eur Heart J"},{"key":"636_CR68","doi-asserted-by":"publisher","first-page":"e0248317","DOI":"10.1371\/journal.pone.0248317","volume":"16","author":"A Perry","year":"2021","unstructured":"Perry A, Loh F, Adamo L, Zhang KW, Deych E, Foraker R, et al. Unsupervised cluster analysis of patients with recovered left ventricular ejection fraction identifies unique clinical phenotypes. PLOS ONE. 2021;16:e0248317. https:\/\/doi.org\/10.1371\/journal.pone.0248317.","journal-title":"PLOS ONE"},{"key":"636_CR69","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1007\/s00392-022-02126-8","volume":"112","author":"V Nuzzi","year":"2023","unstructured":"Nuzzi V, Cannat\u00e0 A, Pellicori P, Manca P, Stolfo D, Gregorio C, et al. Diuretic dose trajectories in dilated cardiomyopathy: prognostic implications. Clin Res Cardiol. 2023;112:419\u201330. https:\/\/doi.org\/10.1007\/s00392-022-02126-8.","journal-title":"Clin Res Cardiol"},{"key":"636_CR70","doi-asserted-by":"publisher","first-page":"3605","DOI":"10.1093\/eurheartj\/ehz554","volume":"40","author":"LE Rohde","year":"2019","unstructured":"Rohde LE, Rover MM, Figueiredo Neto JA, Danzmann LC, Bertoldi EG, Sim\u00f5es MV, et al. Short-term diuretic withdrawal in stable outpatients with mild heart failure and no fluid retention receiving optimal therapy: a double-blind, multicentre, randomized trial. Eur Heart J. 2019;40:3605\u201312. https:\/\/doi.org\/10.1093\/eurheartj\/ehz554.","journal-title":"Eur Heart J"},{"key":"636_CR71","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1136\/hrt.44.2.134","volume":"44","author":"K Swedberg","year":"1980","unstructured":"Swedberg K, Hjalmarson A, Waagstein F, Wallentin I. Adverse effects of beta-blockade withdrawal in patients with congestive cardiomyopathy. Heart. 1980;44:134\u201342. https:\/\/doi.org\/10.1136\/hrt.44.2.134.","journal-title":"Heart"},{"key":"636_CR72","doi-asserted-by":"publisher","first-page":"551","DOI":"10.1161\/01.cir.80.3.551","volume":"80","author":"F Waagstein","year":"1989","unstructured":"Waagstein F, Caidahl K, Wallentin I, Bergh CH, Hjalmarson A. Long-term beta-blockade in dilated cardiomyopathy. Effects of short- and long-term metoprolol treatment followed by withdrawal and readministration of metoprolol. Circulation. 1989;80:551\u201363. https:\/\/doi.org\/10.1161\/01.cir.80.3.551.","journal-title":"Circulation"},{"key":"636_CR73","doi-asserted-by":"publisher","first-page":"456","DOI":"10.1016\/s0002-8703(99)70147-x","volume":"138","author":"S Morimoto","year":"1999","unstructured":"Morimoto S, Shimizu K, Yamada K, Hiramitsu S, Hishida H. Can beta-blocker therapy be withdrawn from patients with dilated cardiomyopathy? Am Heart J. 1999;138:456\u20139. https:\/\/doi.org\/10.1016\/s0002-8703(99)70147-x.","journal-title":"Am Heart J"},{"key":"636_CR74","doi-asserted-by":"publisher","first-page":"e019240","DOI":"10.1161\/JAHA.120.019240","volume":"10","author":"N Enzan","year":"2021","unstructured":"Enzan N, Matsushima S, Ide T, Kaku H, Tohyama T, Funakoshi K, et al. Beta-blocker use is associated with prevention of left ventricular remodeling in recovered dilated cardiomyopathy. J Am Heart Assoc. 2021;10:e019240. https:\/\/doi.org\/10.1161\/JAHA.120.019240.","journal-title":"J Am Heart Assoc"},{"key":"636_CR75","doi-asserted-by":"publisher","first-page":"1557","DOI":"10.1016\/0735-1097(93)90578-o","volume":"22","author":"PW Pflugfelder","year":"1993","unstructured":"Pflugfelder PW, Baird MG, Tonkon MJ, DiBianco R, Pitt B. Clinical consequences of angiotensin-converting enzyme inhibitor withdrawal in chronic heart failure: a double-blind, placebo-controlled study of quinapril. The Quinapril heart failure trial investigators. J Am Coll Cardiol. 1993;22:1557\u201363. https:\/\/doi.org\/10.1016\/0735-1097(93)90578-o.","journal-title":"J Am Coll Cardiol"},{"key":"636_CR76","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1161\/CIRCULATIONAHA.119.044586","volume":"141","author":"SD Solomon","year":"2020","unstructured":"Solomon SD, Vaduganathan M, L Claggett B, Packer M, Zile M, Swedberg K, et al. Sacubitril\/valsartan across the spectrum of ejection fraction in heart failure. Circulation. 2020;141:352\u201361. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.119.044586.","journal-title":"Circulation"},{"key":"636_CR77","doi-asserted-by":"publisher","first-page":"1609","DOI":"10.1056\/NEJMoa1908655","volume":"381","author":"SD Solomon","year":"2019","unstructured":"Solomon SD, McMurray JJV, Anand IS, Ge J, Lam CSP, Maggioni AP, et al. Angiotensin-neprilysin inhibition in heart failure with preserved ejection fraction. N Engl J Med. 2019;381:1609\u201320. https:\/\/doi.org\/10.1056\/NEJMoa1908655.","journal-title":"N Engl J Med"},{"key":"636_CR78","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1161\/CIRCHEARTFAILURE.109.906909","volume":"3","author":"JE Udelson","year":"2010","unstructured":"Udelson JE, Feldman AM, Greenberg B, Pitt B, Mukherjee R, Solomon HA, et al. Randomized, double-blind, multicenter, placebo-controlled study evaluating the effect of aldosterone antagonism with eplerenone on ventricular remodeling in patients with mild-to-moderate heart failure and left ventricular systolic dysfunction. Circ Heart Fail. 2010;3:347\u201353. https:\/\/doi.org\/10.1161\/CIRCHEARTFAILURE.109.906909.","journal-title":"Circ Heart Fail"},{"key":"636_CR79","doi-asserted-by":"publisher","first-page":"725399","DOI":"10.3389\/fcvm.2021.725399","volume":"8","author":"Y Chen","year":"2021","unstructured":"Chen Y, Qiu Z, Jiang J, Su X, Huang F, Tang J, et al. Outcomes of spironolactone withdrawal in dilated cardiomyopathy with improved ejection fraction. Front Cardiovasc Med. 2021;8:725399. https:\/\/doi.org\/10.3389\/fcvm.2021.725399.","journal-title":"Front Cardiovasc Med"},{"key":"636_CR80","doi-asserted-by":"publisher","first-page":"1956","DOI":"10.1038\/s41591-022-01971-4","volume":"28","author":"PS Jhund","year":"2022","unstructured":"Jhund PS, Kondo T, Butt JH, Docherty KF, Claggett BL, Desai AS, et al. Dapagliflozin across the range of ejection fraction in patients with heart failure: a patient-level, pooled meta-analysis of DAPA-HF and DELIVER. Nat Med. 2022;28:1956\u201364. https:\/\/doi.org\/10.1038\/s41591-022-01971-4.","journal-title":"Nat Med"},{"key":"636_CR81","doi-asserted-by":"publisher","first-page":"1089","DOI":"10.1056\/NEJMoa2206286","volume":"387","author":"SD Solomon","year":"2022","unstructured":"Solomon SD, McMurray JJV, Claggett B, de Boer RA, DeMets D, Hernandez AF, et al. Dapagliflozin in heart failure with mildly reduced or preserved ejection fraction. N Engl J Med. 2022;387:1089\u201398. https:\/\/doi.org\/10.1056\/NEJMoa2206286.","journal-title":"N Engl J Med"},{"key":"636_CR82","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1016\/j.jchf.2021.11.006","volume":"10","author":"SD Solomon","year":"2022","unstructured":"Solomon SD, Vaduganathan M, Claggett BL, de Boer RA, DeMets D, Hernandez AF, et al. Baseline characteristics of patients with hf with mildly reduced and preserved ejection fraction: DELIVER trial. JACC Heart Fail. 2022;10:184\u201397. https:\/\/doi.org\/10.1016\/j.jchf.2021.11.006.","journal-title":"JACC Heart Fail"},{"key":"636_CR83","doi-asserted-by":"publisher","first-page":"2504","DOI":"10.1038\/s41591-022-02102-9","volume":"28","author":"O Vardeny","year":"2022","unstructured":"Vardeny O, Fang JC, Desai AS, Jhund PS, Claggett B, Vaduganathan M, et al. Dapagliflozin in heart failure with improved ejection fraction: a prespecified analysis of the DELIVER trial. Nat Med. 2022;28:2504\u201311. https:\/\/doi.org\/10.1038\/s41591-022-02102-9. A pre-specified analysis of the DELIVER trial showing the benefits of SGLT2i in patients with HFimpEF.","journal-title":"Nat Med"},{"key":"636_CR84","doi-asserted-by":"publisher","first-page":"1026","DOI":"10.1002\/ejhf.2073","volume":"23","author":"TA Zelniker","year":"2021","unstructured":"Zelniker TA, Morrow DA, Mosenzon O, Goodrich EL, Jarolim P, Murphy SA, et al. Relationship between baseline cardiac biomarkers and cardiovascular death or hospitalization for heart failure with and without sodium-glucose co-transporter 2 inhibitor therapy in DECLARE-TIMI 58. Eur J Heart Fail. 2021;23:1026\u201336. https:\/\/doi.org\/10.1002\/ejhf.2073.","journal-title":"Eur J Heart Fail"},{"key":"636_CR85","doi-asserted-by":"publisher","first-page":"632","DOI":"10.1016\/j.jacbts.2020.02.004","volume":"5","author":"GD Lopaschuk","year":"2020","unstructured":"Lopaschuk GD, Verma S. Mechanisms of cardiovascular benefits of sodium glucose co-transporter 2 (SGLT2) inhibitors: a state-of-the-art review. JACC Basic Transl Sci. 2020;5:632\u201344. https:\/\/doi.org\/10.1016\/j.jacbts.2020.02.004.","journal-title":"JACC Basic Transl Sci"},{"key":"636_CR86","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1161\/CIRCULATIONAHA.121.056072","volume":"145","author":"A Yafasova","year":"2022","unstructured":"Yafasova A, Butt JH, Elming MB, Nielsen JC, Haarbo J, Videb\u00e6k L, et al. Long-term follow-up of DANISH (the Danish study to assess the efficacy of icds in patients with nonischemic systolic heart failure on mortality). Circulation. 2022;145:427\u201336. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.121.056072.","journal-title":"Circulation"},{"key":"636_CR87","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1161\/CIRCULATIONAHA.118.035452","volume":"140","author":"E Gracia","year":"2019","unstructured":"Gracia E, Hamid A, Butler J. Timely management of new-onset heart failure. Circulation. 2019;140:621\u20133. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.118.035452.","journal-title":"Circulation"},{"key":"636_CR88","doi-asserted-by":"publisher","first-page":"oeab046","DOI":"10.1093\/ehjopen\/oeab046","volume":"2","author":"MC Pastore","year":"2022","unstructured":"Pastore MC, Mandoli GE, Giannoni A, Benfari G, Dini FL, Pugliese NR, et al. Sacubitril\/valsartan reduces indications for arrhythmic primary prevention in heart failure with reduced ejection fraction: insights from DISCOVER-ARNI, a multicenter Italian register. Eur Heart J Open. 2022;2:oeab046. https:\/\/doi.org\/10.1093\/ehjopen\/oeab046.","journal-title":"Eur Heart J Open"},{"key":"636_CR89","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1016\/j.hrthm.2018.11.005","volume":"16","author":"IC Thomas","year":"2019","unstructured":"Thomas IC, Wang Y, See VY, Minges KE, Curtis JP, Hsu JC. Outcomes following implantable cardioverter-defibrillator generator replacement in patients with recovered left ventricular systolic function: the National Cardiovascular Data Registry. Heart Rhythm. 2019;16:733\u201340. https:\/\/doi.org\/10.1016\/j.hrthm.2018.11.005.","journal-title":"Heart Rhythm"},{"key":"636_CR90","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1016\/j.amjcard.2017.04.020","volume":"120","author":"A Smer","year":"2017","unstructured":"Smer A, Saurav A, Azzouz MS, Salih M, Ayan M, Abuzaid A, et al. Meta-analysis of Risk of ventricular arrhythmias after improvement in left ventricular ejection fraction during follow-up in patients with primary prevention implantable cardioverter defibrillators. Am J Cardiol. 2017;120:279\u201386. https:\/\/doi.org\/10.1016\/j.amjcard.2017.04.020.","journal-title":"Am J Cardiol"},{"key":"636_CR91","doi-asserted-by":"publisher","first-page":"767","DOI":"10.1001\/jamacardio.2017.1413","volume":"2","author":"S Adabag","year":"2017","unstructured":"Adabag S, Patton KK, Buxton AE, Rector TS, Ensrud KE, Vakil K, et al. Association of implantable cardioverter defibrillators with survival in patients with and without improved ejection fraction: secondary analysis of the sudden cardiac death in heart failure Trial. JAMA Cardiol. 2017;2:767\u201374. https:\/\/doi.org\/10.1001\/jamacardio.2017.1413.","journal-title":"JAMA Cardiol"},{"key":"636_CR92","doi-asserted-by":"publisher","first-page":"436","DOI":"10.3390\/jcm7110436","volume":"7","author":"D Masarone","year":"2018","unstructured":"Masarone D, Limongelli G, Ammendola E, Verrengia M, Gravino R, Pacileo G. Risk stratification of sudden cardiac death in patients with heart failure: an update. J Clin Med. 2018;7:436. https:\/\/doi.org\/10.3390\/jcm7110436.","journal-title":"J Clin Med"},{"key":"636_CR93","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1016\/j.jchf.2013.12.004","volume":"2","author":"T Ahmad","year":"2014","unstructured":"Ahmad T, Fiuzat M, Neely B, Neely ML, Pencina MJ, Kraus WE, et al. Biomarkers of myocardial stress and fibrosis as predictors of mode of death in patients with chronic heart failure. JACC Heart Fail. 2014;2:260\u20138. https:\/\/doi.org\/10.1016\/j.jchf.2013.12.004.","journal-title":"JACC Heart Fail"},{"key":"636_CR94","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1161\/CIRCOUTCOMES.122.009827","volume":"16","author":"SC Montembeau","year":"2023","unstructured":"Montembeau SC, Merchant FM, Speight C, Kramer DB, Matlock DD, Horn\u00fd M, et al. Patients\u2019 perspectives regarding generator exchanges of implantable cardioverter defibrillators. Circ Cardiovasc Qual Outcomes. 2023;16:509\u201318. https:\/\/doi.org\/10.1161\/CIRCOUTCOMES.122.009827.","journal-title":"Circ Cardiovasc Qual Outcomes"},{"key":"636_CR95","doi-asserted-by":"publisher","first-page":"1001","DOI":"10.1016\/j.jacep.2019.07.012","volume":"5","author":"SY Naqvi","year":"2019","unstructured":"Naqvi SY, Jawaid A, Vermilye K, Biering-S\u00f8rensen T, Goldenberg I, Zareba W, et al. Left ventricular reverse remodeling in cardiac resynchronization therapy and long-term outcomes. JACC Clin Electrophysiol. 2019;5:1001\u201310. https:\/\/doi.org\/10.1016\/j.jacep.2019.07.012.","journal-title":"JACC Clin Electrophysiol"},{"key":"636_CR96","doi-asserted-by":"publisher","first-page":"718","DOI":"10.1016\/j.amjcard.2008.05.009","volume":"102","author":"C Ypenburg","year":"2008","unstructured":"Ypenburg C, Van Bommel RJ, Marsan NA, Delgado V, Bleeker GB, van der Wall EE, et al. Effects of interruption of long-term cardiac resynchronization therapy on left ventricular function and dyssynchrony. Am J Cardiol. 2008;102:718\u201321. https:\/\/doi.org\/10.1016\/j.amjcard.2008.05.009.","journal-title":"Am J Cardiol"},{"key":"636_CR97","doi-asserted-by":"publisher","first-page":"1426","DOI":"10.1016\/j.jacc.2020.01.040","volume":"75","author":"P Nijst","year":"2020","unstructured":"Nijst P, Martens P, Dauw J, Tang WHW, Bertrand PB, Penders J, et al. Withdrawal of neurohumoral blockade after cardiac resynchronization therapy. J Am Coll Cardiol. 2020;75:1426\u201338. https:\/\/doi.org\/10.1016\/j.jacc.2020.01.040. This study examined whether withdrawing neurohormonal blockade in patients with normalized LVEF following CRT is feasible.","journal-title":"J Am Coll Cardiol"},{"key":"636_CR98","doi-asserted-by":"publisher","first-page":"1113","DOI":"10.1093\/eurjhf\/hft071","volume":"15","author":"IH Kraai","year":"2013","unstructured":"Kraai IH, Vermeulen KM, Luttik MLA, Hoekstra T, Jaarsma T, Hillege HL. Preferences of heart failure patients in daily clinical practice: quality of life or longevity? Eur J Heart Fail. 2013;15:1113\u201321. https:\/\/doi.org\/10.1093\/eurjhf\/hft071.","journal-title":"Eur J Heart Fail"},{"key":"636_CR99","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1093\/ehjcvp\/pvaa097","volume":"7","author":"AA Rasmussen","year":"2021","unstructured":"Rasmussen AA, Wiggers H, Jensen M, Berg SK, Rasmussen TB, Borregaard B, et al. Patient-reported outcomes and medication adherence in patients with heart failure. Eur Heart J - Cardiovasc Pharmacother. 2021;7:287\u201395. https:\/\/doi.org\/10.1093\/ehjcvp\/pvaa097.","journal-title":"Eur Heart J - Cardiovasc Pharmacother"},{"key":"636_CR100","doi-asserted-by":"publisher","first-page":"1209","DOI":"10.2147\/PPA.S410371","volume":"17","author":"AS Jarab","year":"2023","unstructured":"Jarab AS, Al-Qerem WA, Hamam HW, Alzoubi KH, Abu Heshmeh SR, Mukattash TL, et al. Medication adherence and its associated factors among outpatients with heart failure. Patient Prefer Adherence. 2023;17:1209\u201320. https:\/\/doi.org\/10.2147\/PPA.S410371.","journal-title":"Patient Prefer Adherence"},{"key":"636_CR101","doi-asserted-by":"publisher","first-page":"966537","DOI":"10.3389\/fcvm.2022.966537","volume":"9","author":"P Li","year":"2022","unstructured":"Li P, Luo X, Hou C, Wu S, Wang L, Sun N, et al. Maintenance of recovered dilated cardiomyopathy patients with half-dose neurohumoral blockades (MED-CHARM): a protocol for an open-label, pilot, randomized trial. Front Cardiovasc Med. 2022;9:966537. https:\/\/doi.org\/10.3389\/fcvm.2022.966537.","journal-title":"Front Cardiovasc Med"}],"container-title":["Current Heart Failure Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11897-023-00636-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11897-023-00636-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11897-023-00636-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,12,22]],"date-time":"2023-12-22T11:19:12Z","timestamp":1703243952000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11897-023-00636-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11,24]]},"references-count":101,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2023,12]]}},"alternative-id":["636"],"URL":"https:\/\/doi.org\/10.1007\/s11897-023-00636-8","relation":{},"ISSN":["1546-9530","1546-9549"],"issn-type":[{"value":"1546-9530","type":"print"},{"value":"1546-9549","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,11,24]]},"assertion":[{"value":"6 November 2023","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 November 2023","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"This article does not contain any studies with human or animal subjects performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human and Animal Rights and Informed Consent"}}]}}